Back to News & Events

Ohr Pharmaceutical & Cold Spring Harbor Laboratory Announce Joint Venture

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and Cold Spring Harbor Laboratory (CSHL) have announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

The new joint venture will be a private entity, initially with equal ownership by Ohr and Cold Spring Harbor Laboratory. The two partners will seek funding and contribute to the research and development of trodusquemine and also newly patented analogs. The goal is to take the program into the clinic and to demonstrate proof of concept.

Andreas Grill, former Executive Director of Forest Research Institute for Forest Laboratories, Inc and current Center for Biotechnology BioEntrepreneur-inResidence has been tapped to serve as Chief Executive Office for DepYmed.

Read the full press release here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4445 [post_author] => 4 [post_date] => 2024-06-10 15:37:44 [post_date_gmt] => 2024-06-10 19:37:44 [post_content] =>

Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. This round included investments from existing supporters Third Kind Venture Capital, Empire State Development, and Red Cell Partners, as well as new strategic investor Bristol Myers Squibb, which has been collaborating with Envisagenics on oncology research since 2022.

Read more about Envisagenics Series B award here.

[post_title] => CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => envisagenics-secures-25-million-series-b-funding-to-advance-rna-splicing-therapeutics [to_ping] => [pinged] => [post_modified] => 2025-05-01 12:39:53 [post_modified_gmt] => 2025-05-01 16:39:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4445 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3225 [post_author] => 3 [post_date] => 2019-04-05 19:35:45 [post_date_gmt] => 2019-04-05 19:35:45 [post_content] => Join the Center for Biotechnology for Roche Oncology Strategic Interests Presentation on Monday April 15, 2019. Fiona Mack, PhD, Director External Innovation, Pharmaceutical Research and Early Development for the Roche Innovation Center New York will be at Stony Brook University Medical Center to present Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. Fiona will also discuss Roche’s approach to investing in emerging novel therapeutics utilizing case studies as examples. April 15, 2019 10am-11am Radiation Oncology Conference Room (HOS L2-664) Stony Brook University Medical Center Level 2 Seating is limited. If you are interested in attending please contact Emily Kao at emily.kao@stonybrook.edu How to get to Stony Brook University Hospital Radiation Oncology Conference Room To access the Radiation Oncology Conference Room, please utilize the hospital main elevators and take down to Level 2. When you arrive on Level two proceed forward, following the signs to the "green elevators". You will find the Radiation Oncology conference room on your right hand side, room HOS L2-664 [post_title] => Roche Oncology: Strategic Interests Presentation [post_excerpt] => Join the Center for Biotechnology for a presentation on Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => roche-oncology-strategic-interests-presentation [to_ping] => [pinged] => [post_modified] => 2019-04-05 19:57:03 [post_modified_gmt] => 2019-04-05 19:57:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3225 [menu_order] => 98 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3820 [post_author] => 4 [post_date] => 2021-09-20 15:59:29 [post_date_gmt] => 2021-09-20 15:59:29 [post_content] =>

NYSTAR and FuzeHub invite you to the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. This multi-day event for NYS organizations that want to showcase and discover new and emerging technologies that support innovation and drive business growth. Whether you’re a startup, an economic developer, or an established manufacturer, the NYS Innovation Summit is for you.

The 2021 New York State Innovation Summit will showcase companies and researchers at the forefront of emerging technologies and new advancements in production capabilities. This event celebrates New York State leadership in technology-led economic growth with experts in biotechnology, new materials, energy innovation, and artificial intelligence that will explore current technology convergence opportunities, ways to accelerate commercialization, and issues of manufacturing sustainability.

This year’s Innovation Summit includes the New York State Commercialization Competition and speakers from top companies such as Cree, Plug Power, Velan Studios and Verizon 5G Labs.

For more information, or to register, visit nysinnovationsummit.com.

[post_title] => New York State Innovation Summit [post_excerpt] => NYSTAR and FuzeHub present the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => new-york-state-innovation-summit [to_ping] => [pinged] => [post_modified] => 2022-08-22 13:09:12 [post_modified_gmt] => 2022-08-22 13:09:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3820 [menu_order] => 37 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 270 [max_num_pages] => 90 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics

More Information

Roche Oncology: Strategic Interests Presentation

More Information

New York State Innovation Summit

More Information